Cargando…

695. Activity of Imipenem–Relebactam and Ceftolozane–Tazobactam Against a Contemporary Collection of Gram-Negative Bacteria from New York City

BACKGROUND: Carbapenem-resistant Gram-negative bacteria are important nosocomial pathogens, and therapeutic options are often limited. METHODS: Clinical isolates were gathered during a surveillance study in 2017 involving 7 hospitals in Brooklyn, NY. Isolates underwent susceptibility testing using t...

Descripción completa

Detalles Bibliográficos
Autores principales: Iregui, Alejandro, Khan, Zeb, Landman, David, Quale, John M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811245/
http://dx.doi.org/10.1093/ofid/ofz360.763
_version_ 1783462434762129408
author Iregui, Alejandro
Khan, Zeb
Landman, David
Quale, John M
author_facet Iregui, Alejandro
Khan, Zeb
Landman, David
Quale, John M
author_sort Iregui, Alejandro
collection PubMed
description BACKGROUND: Carbapenem-resistant Gram-negative bacteria are important nosocomial pathogens, and therapeutic options are often limited. METHODS: Clinical isolates were gathered during a surveillance study in 2017 involving 7 hospitals in Brooklyn, NY. Isolates underwent susceptibility testing using the agar dilution method; for the combination of imipenem-relebactam and ceftolozane-tazobactam, the concentrations of relebactam and tazobactam were fixed at 4 µg/mL. Breakpoints were defined according to CLSI criteria; for imipenem-relebactam, the breakpoint of imipenem was utilized. Isolates were screened by PCR for common carbapenemases. RESULTS: Overall susceptibility patterns are given in the Table. Of 1805 isolates of E. coli (including 4 with bla(KPC)), 100% were susceptible to imipenem and imipenem-relebactam. Of 503 isolates of K. pneumoniae (including 19 isolates with bla(KPC)), all were susceptible to imipenem-relebactam. Of 171 isolates of Enterobacter spp. (including 3 with bla(KPC)), 100% were susceptible to imipenem-relebactam. Of 260 isolates of P. aeruginosa, 96% were susceptible to imipenem-relebactam and nearly all to ceftolozane-tazobactam. Against A. baumannii, the activity of imipenem-relebactam was the same as imipenem and the ceftolozane-tazobactam MIC was ≤ 4 µg/mL in 65% of isolates. CONCLUSION: Imipenem-relebactam possesses promising activity against multidrug-resistant Enterobacteriaceae endemic to New York City. Ceftolozane-tazobactam demonstrated excellent activity against P. aeruginosa, including isolates resistant to carbapenems. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6811245
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68112452019-10-29 695. Activity of Imipenem–Relebactam and Ceftolozane–Tazobactam Against a Contemporary Collection of Gram-Negative Bacteria from New York City Iregui, Alejandro Khan, Zeb Landman, David Quale, John M Open Forum Infect Dis Abstracts BACKGROUND: Carbapenem-resistant Gram-negative bacteria are important nosocomial pathogens, and therapeutic options are often limited. METHODS: Clinical isolates were gathered during a surveillance study in 2017 involving 7 hospitals in Brooklyn, NY. Isolates underwent susceptibility testing using the agar dilution method; for the combination of imipenem-relebactam and ceftolozane-tazobactam, the concentrations of relebactam and tazobactam were fixed at 4 µg/mL. Breakpoints were defined according to CLSI criteria; for imipenem-relebactam, the breakpoint of imipenem was utilized. Isolates were screened by PCR for common carbapenemases. RESULTS: Overall susceptibility patterns are given in the Table. Of 1805 isolates of E. coli (including 4 with bla(KPC)), 100% were susceptible to imipenem and imipenem-relebactam. Of 503 isolates of K. pneumoniae (including 19 isolates with bla(KPC)), all were susceptible to imipenem-relebactam. Of 171 isolates of Enterobacter spp. (including 3 with bla(KPC)), 100% were susceptible to imipenem-relebactam. Of 260 isolates of P. aeruginosa, 96% were susceptible to imipenem-relebactam and nearly all to ceftolozane-tazobactam. Against A. baumannii, the activity of imipenem-relebactam was the same as imipenem and the ceftolozane-tazobactam MIC was ≤ 4 µg/mL in 65% of isolates. CONCLUSION: Imipenem-relebactam possesses promising activity against multidrug-resistant Enterobacteriaceae endemic to New York City. Ceftolozane-tazobactam demonstrated excellent activity against P. aeruginosa, including isolates resistant to carbapenems. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811245/ http://dx.doi.org/10.1093/ofid/ofz360.763 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Iregui, Alejandro
Khan, Zeb
Landman, David
Quale, John M
695. Activity of Imipenem–Relebactam and Ceftolozane–Tazobactam Against a Contemporary Collection of Gram-Negative Bacteria from New York City
title 695. Activity of Imipenem–Relebactam and Ceftolozane–Tazobactam Against a Contemporary Collection of Gram-Negative Bacteria from New York City
title_full 695. Activity of Imipenem–Relebactam and Ceftolozane–Tazobactam Against a Contemporary Collection of Gram-Negative Bacteria from New York City
title_fullStr 695. Activity of Imipenem–Relebactam and Ceftolozane–Tazobactam Against a Contemporary Collection of Gram-Negative Bacteria from New York City
title_full_unstemmed 695. Activity of Imipenem–Relebactam and Ceftolozane–Tazobactam Against a Contemporary Collection of Gram-Negative Bacteria from New York City
title_short 695. Activity of Imipenem–Relebactam and Ceftolozane–Tazobactam Against a Contemporary Collection of Gram-Negative Bacteria from New York City
title_sort 695. activity of imipenem–relebactam and ceftolozane–tazobactam against a contemporary collection of gram-negative bacteria from new york city
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811245/
http://dx.doi.org/10.1093/ofid/ofz360.763
work_keys_str_mv AT ireguialejandro 695activityofimipenemrelebactamandceftolozanetazobactamagainstacontemporarycollectionofgramnegativebacteriafromnewyorkcity
AT khanzeb 695activityofimipenemrelebactamandceftolozanetazobactamagainstacontemporarycollectionofgramnegativebacteriafromnewyorkcity
AT landmandavid 695activityofimipenemrelebactamandceftolozanetazobactamagainstacontemporarycollectionofgramnegativebacteriafromnewyorkcity
AT qualejohnm 695activityofimipenemrelebactamandceftolozanetazobactamagainstacontemporarycollectionofgramnegativebacteriafromnewyorkcity